Women’s Health at ViVE 2026
What Market Signals Are. And What to Do About Them.
Women’s health is finally moving, but it remains significantly under-funded and under-served relative to its potential. While the broader digital health market has faced a valuation reset, women’s health has shown remarkable resilience. With $5.4 billion of VC funding between 2020 and 2024 and $1.2 billion in 2024 alone, femtech has demonstrated sustained momentum (PitchBook, 2025). With the US women’s digital health market projected to grow 19% annually to reach $3.3 billion by 2030 (Grand View Research, 2024), the opportunity is no longer a niche. It is a core market driver.
The VC environment is shifting from “growth at all costs” to “clinical-first” models. The nature of femtech deals is evolving, as we are seeing a growing investor appetite for non-software plays, with diagnostics and biopharma taking a larger share of total capital (Silicon Valley Bank, 2026). This quality-driven approach favors companies that can prove clinical utility and a clear path to ROI, moving beyond simple tracking apps toward holistic care for conditions like PCOS and hormonal health.
From the panels at the recent ViVE conference featuring Ōura, Maven Clinic, HLTH, BillionToOne, and Ascension, along with hallway conversations, we identified several key actionable themes. For operators focused on women’s health initiatives, here are some key insights for investors, executives, interim leaders, and on-demand consultants.
Access first, AI second
Market signals: The real gap is access: timely triage, navigation, and follow-up — rather than “more data”. AI helps only when reimbursement and workflows carry it to patients.
Execution priorities:
- Evidence payers can use: utilization, adherence, avoidable ED/imaging/procedures, and ≤12‑month total cost impact.
- A defined payment path: existing CPT/HCPCS/CMS coverage or employer benefit design, with unit economics and prior-authorization guidance.
- A 90‑day pilot plan: target cohort, volume, integration steps, staffing, success thresholds, and off-ramps.
Break silos, overlap lanes
Market signals: Institutional buyers like health systems executives, payers, and employer benefit leaders favor “rave overlaps” across payers, healthcare delivery providers, and technology vendors that blend disruption with collaboration. Co-delivery reduces organizational risk and speeds adoption.
Execution priorities:
- Clinical guardrails: physician oversight, escalation protocols, documentation standards, and quality metrics.
- Integration points: FHIR/HL7 endpoints (patient, observation, and care plan), ADT feeds, referral loops, and care management handoffs.
- Shared accountability: co-branded clinical protocols, joint KPI dashboards, and clearly defined support SLAs.
Trust is built when patients feel well, not sick
Market signals: Baseline trust in institutions can be lower among women. Credible clinical voices and transparent content governance lift engagement and adherence.
Execution priorities:
- Clinician-fronted experience: visible OB/GYN, URO-GYN, and menopause leadership, proactive outreach and follow-up, named medical advisors and disclosures.
- Misinformation mitigation: editorial standards, clinician sign-off, provenance/audit logs, and patient-friendly summaries.
- Safety transparency: model cards and known limitations for AI features, feedback channels, and resolution timelines.
Diagnostics that unlock therapeutics
Market signals: Health systems, payers, and employers want diagnostics that directly enable targeted therapy, such as endometriosis, fertility, cardio‑metabolic risks unique to women, paired with operator-ready care pathways.
Execution priorities:
- Full handoff design: coverage references, prior-auth playbooks, referral routing, pharmacy/infusion coordination, and navigation.
- Outcome tracking: time‑to‑diagnosis, therapy initiation, adherence, and condition‑specific outcomes.
- Commercial clarity: bundles with virtual care/specialist networks, SOPs that go beyond a lab result.
At‑home collection is mainstreaming — design for it
Market signals: At-home sampling, such as dried blood spot and capillary collection, is moving from pilot to standard in trials and chronic programs, improving adherence and reach.
Execution priorities:
- Logistics and quality: kit supply chain, chain of custody, labeling, turnaround SLAs, strong customer experience, and error handling.
- Clinical equivalence: validation vs. in‑clinic draws, QC procedures, and mitigation for insufficient samples.
- Reimbursement and UX: coverage and cost transparency, multilingual instructions, disability‑inclusive design, and support.
At WittKieffer, we have previously explored how capturing the market momentum in women’s health requires a shift in both executive talent and commercial strategy. Our research highlights that the $100 billion opportunity in women’s health demands a new type of leader — one who can navigate the nuances of gender-specific care while managing complex health system partnerships (WittKieffer, 2026). Additionally, for many innovators, the self-pay pathway serves as a critical strategic bridge, allowing companies to build evidence and user trust while working toward long-term reimbursement (WittKieffer, 2025). This focus on leadership and consumer-empowered insights is central to advancing women’s health within the Quality of Life Ecosystem.
Panel and sources
Panelists observed: Ōura (Chris Curry, MD, PhD), Maven Clinic (Danielle Dang, MD), HLTH (Jody Tropeano Greene), BillionToOne (Oguzhan Atay, PhD), Ascension (Kimberly Wells).
Sources
Grand View Research (2024). US Women’s Digital Health Market Size & Outlook, 2023-2030.
PitchBook (2025). Femtech VC Market Snapshot. February 2025.
Silicon Valley Bank (2026). Healthcare Industry Trends, H1 2026 Report.
WittKieffer (2025). The Self-Pay Pathway: A Strategic Bridge Between Innovation and Reimbursement in US Healthcare.
WittKieffer (2026). The Leadership Gap in Women’s Health: Why $100 Billion in Opportunity Demands a New Executive Profile.
